Weil Company Inc. Lowers Stock Holdings in VBI Vaccines Inc. (NASDAQ:VBIV)

Weil Company Inc. lowered its position in shares of VBI Vaccines Inc. (NASDAQ:VBIV) by 36.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 56,685 shares of the biopharmaceutical company’s stock after selling 32,728 shares during the period. Weil Company Inc.’s holdings in VBI Vaccines were worth $176,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sax Wealth Advisors LLC acquired a new position in VBI Vaccines in the 4th quarter valued at about $28,000. Argent Advisors Inc. acquired a new position in VBI Vaccines in the 1st quarter valued at about $34,000. Wealth Management Partners LLC acquired a new position in VBI Vaccines in the 4th quarter valued at about $35,000. Truist Financial Corp acquired a new position in VBI Vaccines in the 4th quarter valued at about $35,000. Finally, Teacher Retirement System of Texas purchased a new stake in VBI Vaccines in the 4th quarter valued at approximately $37,000. Institutional investors and hedge funds own 47.94% of the company’s stock.

VBIV stock opened at $4.06 on Friday. VBI Vaccines Inc. has a 1 year low of $2.05 and a 1 year high of $6.93. The company has a current ratio of 6.11, a quick ratio of 6.02 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $3.07. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -17.87 and a beta of 2.01.

VBI Vaccines (NASDAQ:VBIV) last posted its earnings results on Monday, May 10th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). VBI Vaccines had a negative net margin of 5,862.62% and a negative return on equity of 34.48%. The company had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.51 million. On average, analysts anticipate that VBI Vaccines Inc. will post -0.3 EPS for the current year.

VBIV has been the topic of a number of analyst reports. Jefferies Financial Group initiated coverage on VBI Vaccines in a report on Thursday, February 25th. They issued a “buy” rating and a $7.00 price objective on the stock. Zacks Investment Research raised VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Tuesday, May 11th. Finally, Raymond James started coverage on VBI Vaccines in a research note on Friday, May 21st. They set a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $7.00.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Recommended Story: What is net income?

Want to see what other hedge funds are holding VBIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VBI Vaccines Inc. (NASDAQ:VBIV).

Institutional Ownership by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.